Sign in
TerminatedPhase 1

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
60 people enrolled
Started
13 Feb 2023
Ended
5 Aug 2024
Type of study
Interventional, 5 groups
Treatments tested
  • Relugolix Pill
  • Ritonavir
  • Itraconazole
Record updated
19 September 2024
Why it stopped
Terminated by the PI

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Must have histologically or cytologically confirmed prostate cancer with plans to start medical castration therapy
  • Age 18 or older. Because no dosing or adverse event data are currently available on the use of relugolix in combination with itraconazole or ritonavir in patients <18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group performance status ≤2 (Karnofsky ≥60%)
  • Participants must satisfy the following laboratory criteria:
  • Testosterone > 200 ng/dl
  • QTc within normal limits
  • Aspartate Transferase (AST)/alanine transaminase (ALT) < 3x upper limit of normal
  • Ability to take oral medication and be willing to adhere to the medication regimen
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Concurrent therapy with strong interacting drugs with CYP3A4 and P-gp (See Appendix list of strong inhibitors or inducers) due to concerning possible drug-drug interactions with itraconazole, ritonavir and relugolix. Potential drug-drug interactions will also be reviewed by study investigators prior to enrollment
  • Patients receiving treatment with another investigational drug or other intervention within 3 expected half-lives of the agent
  • Need for combination systemic therapy for prostate cancer including docetaxel and/or second-generation androgen receptor pathway targeted agents (i.e. abiraterone, enzalutamide, apalutamide, darolutamide, etc)
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to relugolix, itraconazole or ritonavir
  • Serious or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
  • New York Heart Association Class III of IV congestive heart failure
  • Active psychiatric illness/social situations that would limit compliance with protocol requirements
  • Known gastrointestinal malabsorption

Where in United States

  • University of Chicago Comprehensive Cancer CenterChicago, United States

About the trial

What the trial wants to find out

Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. This study is for individuals who have advanced prostate cancer and plans to have medical castration (the use of medications or chemicals to lower hormone production in the testicles). Your participation in this research will last up to 1 month.

Read full original descriptionShow less

The purpose of this research is to gather information on the safety and effectiveness of relugolix in combination with ritonavir or itraconazole. The goal of this research is to find out if combining two medications (relugolix and itraconazole or relugolix and ritonavir) could possibly lead to using less relugolix, which is an expensive drug.

The 5 groups in the trial

  • Study Group 1Treatment being tested

    All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 1 will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7

    Treatment: Relugolix Pill

  • Study Group 2aTreatment being tested

    All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 2a will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7 * Itraconazole (200 mg) on Days 1-14

    Treatment: Relugolix Pill and Itraconazole

  • Study Group 2bTreatment being tested

    All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 2b will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7 * Ritonavir (100 mg tablets taken by mouth) on Days 1-14

    Treatment: Relugolix Pill and Ritonavir

  • Study Group 3aTreatment being tested

    All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 3a will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-4 * Itraconazole (200 mg tablets taken by mouth) on Days 1-14

    Treatment: Relugolix Pill and Itraconazole

  • Study Group 3bTreatment being tested

    All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 3b will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-4 * Ritonavir (100 mg) on Days 1-14

    Treatment: Relugolix Pill and Ritonavir

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and Pg-P Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients
Record updated
19 September 2024